|
MarketWatch
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Christopher P. Adams and
Van V. Brantner
This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues ("The Price of Innovation"), using their published cost estimates along with information on success rates and durations from a publicly available data set. For drugs entering human clinical trials for the first time between 1989 and 2002, the paper estimated the cost per new drug to be $868 million. However, our estimates vary from around $500 million to more than $2,000 million, depending on the therapy or the developing firm.

What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Seruga, P. C. Hertz, L. W. Le, and I. F. Tannock
Global drug development in cancer: a cross-sectional study of clinical trial registries
Ann. Onc.,
October 8, 2009;
(2009)
mdp403v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Chen and M. Weir
The Long Shadow of the Past: Risk Pooling and the Political Development of Health Care Reform in the States
Journal of Health Politics Policy and Law,
October 1, 2009;
34(5):
679 - 716.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. McJoynt, M. A. Hirzallah, D. V. Satele, J. H. Pitzen, S. R. Alberts, and S. V. Rajkumar
Building a Protocol Expressway: The Case of Mayo Clinic Cancer Center
J. Clin. Oncol.,
August 10, 2009;
27(23):
3855 - 3860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Meropol, D. Schrag, T. J. Smith, T. M. Mulvey, R. M. Langdon Jr, D. Blum, P. A. Ubel, and L. E. Schnipper
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
J. Clin. Oncol.,
August 10, 2009;
27(23):
3868 - 3874.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Boguski, K. D. Mandl, and V. P. Sukhatme
Repurposing with a Difference
Science,
June 12, 2009;
324(5933):
1394 - 1395.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Johnston
The 2008 William M. Feinberg Lecture: Prioritizing Stroke Research
Stroke,
December 1, 2008;
39(12):
3431 - 3436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. El-Maraghi and E. A. Eisenhauer
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
J. Clin. Oncol.,
March 10, 2008;
26(8):
1346 - 1354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yao and A. Rzhetsky
Quantitative systems-level determinants of human genes targeted by successful drugs
Genome Res.,
February 1, 2008;
18(2):
206 - 213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Fiorino
Industry, Clinical Trials, and the Cost of Cancer Drugs: An Investor's Perspective
J. Clin. Oncol.,
July 1, 2007;
25(19):
e21 - e23.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Hoffman, N. D. Shah, L. C. Vermeulen, G. T. Schumock, P. Grim, R. J. Hunkler, and K. M. Hontz
Projecting future drug expenditures--2007
Am. J. Health Syst. Pharm.,
February 1, 2007;
64(3):
298 - 314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Meropol and K. A. Schulman
Cost of Cancer Care: Issues and Implications
J. Clin. Oncol.,
January 10, 2007;
25(2):
180 - 186.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. DiMasi and H. G. Grabowski
Economics of New Oncology Drug Development
J. Clin. Oncol.,
January 10, 2007;
25(2):
209 - 216.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Comments:
Read all Comments
- Data Source Might Be Subject To Significant Bias
- Kevin Outterson
- Health Affairs, 7 Mar 2006
[Full text]
|